Garry E. Menzel, Ph.D.
Dr. Menzel joined TCR2 Therapeutics (NASDAQ: TCRR), a clinical stage oncology company with three novel immunotherapies for solid tumors and hematological malignancies, in 2016 as a Director and Chief Executive Officer.
Garry was also a founding board member of Fierce 15 award winner Black Diamond Therapeutics (NASDAQ: BDTX), a clinical stage precision oncology company, and currently serves as chair of the audit committee.
Prior to TCR2 Therapeutics, he was the Chief Financial Officer at kidney dialysis and primary care physician company DaVita Healthcare (NYSE: DVA) and the Chief Operating Officer at microRNA therapy company Regulus Therapeutics (NASDAQ: RGLS). He also had global leadership roles as a Managing Director running the biotechnology practices at Goldman Sachs and Credit Suisse. In addition, he was a consultant with Bain & Company.
Dr. Menzel earned his Ph.D. from the University of Cambridge for studying the regulation of oncogenes in immune cells. He also has a M.B.A. from the Stanford Graduate School of Business and a Bachelor of Science degree, with honors, in Biochemistry from Imperial College.
He has served on the National Board of the Epilepsy Foundation since 2003.